Surrey Heartlands

Joint Formulary & PAD

Faricimab - Retinal Vein Occlusion

You are here : Home > Formulary Search > Faricimab - Retinal Vein Occlusion

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravitreal injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
R
Restrictions / Comments :
Important
For place in therapy see guidelines on PAD
Documents :
 
Evidence Review
Faricimab in RVO- NICE briefing - November 2024.pdf
Webpage
NICE TA1004 - Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion - September 2024

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Faricimab
Indication :
Retinal Vein Occlusion
Group Name :
Keywords :
RVO, Branch, BRVO, CRVO, central, intravitreal injection, NICE
Brand Names Include :
Vabysmo
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Retinal Vein Occlusion
Supporting Documents :
2

Other Indications

Below are listed other indications that Faricimab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Retinal Vein Occlusion.

Committee Recommendations (1)

06 Nov 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves faricimab for the treatment of visual impairment caused by macular oedema after retinal vein occlusion as recommended by NICE TA1004

Faricimab for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care.